Technology Listings

Decision Support System for Intravenous Insulin Infusion


Planning the insulin infusion rate for patient treatment in acute care and outpatient settings.

Key Benefits
  • Reduces the risk of hypoglycemia.
  • Allows the user to assign glycemic targets according to patient condition.
  • Novel algorithm provides a more flexible target glucose range compared to existing methods.
Technical Summary

Patients under medical stress are often unable to produce amounts of insulin sufficient to meet their basic metabolic needs. Having abnormally low or high levels of glucose complicates therapy and recovery. Under some conditions, the subcutaneous route of administration for insulin is inflexible, ineffective, or unsafe. Thus, in appropriate settings, intravenous insulin infusion is used regulate blood glucose levels. This process involves the managing of the insulin infusion rate, which is dependent on the blood glucose of the patient and the response to previous insulin therapy. Since the glucose level and condition of the patient are not constant, the insulin infusion rate must be adjusted consistently after each glucose measurement. The decision support system is designed to automatically recommend the insulin infusion rate for patient treatment.

A novel algorithm has been developed for software that calculates the insulin infusion rate. Following data entry by the healthcare professional, which include previous insulin infusion rate, test time, and blood glucose, the software will calculate and report the insulin infusion rate and the next blood glucose test time. Software based on the algorithm will allow the user to input a glycemic target, which provides greater flexibility in the treatment of various patient populations compared to existing methods.

Product Development

Using historical patient insulin treatment data involving another insulin infusion rate protocol, theoretical calculations suggest the novel algorithm is safe and may actually provide shorter time to achieve a target blood glucose level. Software incorporating the algorithm is currently under development. Patient trials to demonstrate proof-of-principle are planned following development of the software.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Nationalized PCT - United States United States 12/513,426 8,721,584 11/2/2007 5/13/2014 9/13/2030
Tech ID: 08126
Published: 4/29/2009

Cliff Michaels
Assistant Director
Emory University

Guillermo Umpierrez
Susan Braithwaite

Metabolic Diseases